Latest Market Share News

National Australia Bank’s half year to March 2026 saw revenue climb 8.7% to $11.16 billion while net profit dropped 19.3%, hit by a $949 million accelerated software amortisation. Excluding this, cash earnings edged 2.3% higher, underpinned by strong business banking growth and cautious credit provisioning amid geopolitical uncertainty.

hipages Group (ASX:HPG) has kicked off an on-market buy-back of up to 10% of its shares, signalling confidence in its undervalued stock amid strong cash flow and growth.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Metal Powder Works has scaled its NextGen powder production to 100 metric tonnes per annum with an industry-leading saleable yield above 95%, setting the stage for an 800MT capacity by 2028 at a fraction of conventional costs.

Pacific Equity Partners has tabled a non-binding offer to acquire oOh!media for A$1.40 per share via a scheme of arrangement, triggering a strategic review by the board amid regulatory hurdles and due diligence conditions.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Central Petroleum lifted March quarter sales revenue to $11.3 million, driven by higher gas volumes and prices, while securing a significant multi-year gas supply deal with the Northern Territory Government that supports a 40% production capacity increase at Palm Valley.

dorsaVi is pivoting from wearable sensors to powering next-gen exoskeletons, leveraging its neuromorphic RRAM technology to tap a projected $2 billion market by 2033.

Carnarvon Energy is gearing up for a high-impact Bedout Sub-basin drilling campaign in the first half of 2027, supported by a robust balance sheet and strategic investments.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Saferoads Holdings maintained steady sales in the March quarter with a positive operating cash flow and ongoing product upgrades, despite cost pressures from oil-based materials and uncertainty over future orders from On-site Rentals.

Eagers Automotive delivered a record $13 billion revenue in 2025, boosted market share in new and New Energy Vehicles, and secured landmark global partnerships to fuel future growth.